Literature DB >> 22487773

Expanding the Evidence Base: Comparing Randomized Controlled Trials and Observational Studies of Statins.

Dan Atar1, Seleen Ong, Peter J Lansberg.   

Abstract

It is widely accepted that randomized controlled trials (RCTs) are the gold standard for demonstrating the efficacy of a given therapy (results under ideal conditions). Observational studies, on the other hand, can complement this by demonstrating effectiveness (results under real-world conditions). To examine the role that observational studies can play in complementing data from RCTs, we reviewed published studies for statins, a class of drugs that have been widely used to reduce the risk of cardiovascular (CV) events by lowering low-density lipoprotein cholesterol levels. RCTs have consistently demonstrated the benefits of statin treatment in terms of CV risk reduction and have demonstrated that more intensive statin therapy has incremental benefits over less intensive treatment. Observational studies of statin use in 'real-world' populations have served to augment the evidence base generated from statin RCTs in preselected populations of patients who are often at high CV risk and have led to similar safety and efficacy findings. They have also raised questions about factors affecting medication adherence, under-treatment, switching between statins, and failure to reach low-density lipoprotein cholesterol target levels, questions for which the answers could lead to improved patient care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 22487773     DOI: 10.1097/MJT.0b013e318245ce94

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

Review 1.  Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?

Authors:  Timothy J Shoemaker; Tatsuyoshi Kono; Cary N Mariash; Carmella Evans-Molina
Journal:  Endocr Pract       Date:  2012 Nov-Dec       Impact factor: 3.443

2.  Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2018-11-14       Impact factor: 3.630

3.  Prior medication adherence of participants and non participants of a randomized controlled trial to improve patient adherence in cardiovascular risk management.

Authors:  A Sieben; S J H Bredie; J C H B M Luijten; C J H M van Laarhoven; S van Dulmen; H A W van Onzenoort
Journal:  BMC Med Res Methodol       Date:  2019-05-09       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.